Drug Profile
Erythromycin - Biostar
Alternative Names: Erythromycin estolate - BiostarLatest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Shaanxi Weinan Aoxing Pharmaceuticals
- Developer BioStar Pharmaceuticals; Shaanxi Weinan Aoxing Pharmaceuticals
- Class Antibacterials; Macrolides
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Inflammation; Sepsis